CO41 Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease
Abstract
Authors
T.H. Shen J.F. Farley